Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             149 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist Díaz-Mataix, Llorenç
 2006
 16 Supplement 5 p. 288-296
9 p.
 artikel
2 Animal models of human behaviour: can they help in understanding pathology and in drug development? Rodgers, R.J.
 2006
 16 Supplement 5 p. S37-S39
3 p.
 artikel
3 Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test Farzin, Davood
 2006
 16 Supplement 5 p. 324-328
5 p.
 artikel
4 Anxiety and ethanol consumption in victorious and defeated mice; effect of κ-opioid receptor activation Kudryavtseva, Natalia
 2006
 16 Supplement 5 p. 504-511
8 p.
 artikel
5 Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia De Luca, Vincenzo
 2006
 16 Supplement 5 p. 268-271
4 p.
 artikel
6 Association study of a functional cathechol-O-methyltransferase polymorphism and cognitive remediation in schizophrenia Bosia, M.
 2006
 16 Supplement 5 p. S67-S68
2 p.
 artikel
7 Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders Yu, Younger W.-Y.
 2006
 16 Supplement 5 p. 498-503
6 p.
 artikel
8 Author Index 2006
 16 Supplement 5 p. S593-S610
18 p.
 artikel
9 Brain mechanisms in pharmacological and behavioral treatment of anxiety Fredrikson, M
 2006
 16 Supplement 5 p. S65-
1 p.
 artikel
10 C.03.01 Can we only treat dopamine dysregulation? Murray, R.
 2006
 16 Supplement 5 p. S573-
1 p.
 artikel
11 C.18.03 Current therapeutic options for negative symptoms Möller, H.J.
 2006
 16 Supplement 5 p. S589-
1 p.
 artikel
12 C.03.04 Do we need another atypical antipsychotic? Kasper, S.
 2006
 16 Supplement 5 p. S574-
1 p.
 artikel
13 C.10.01 Generalized anxiety disorder (GAD): the treatment implications of clinical heterogeneity Bandelow, B.
 2006
 16 Supplement 5 p. S579-
1 p.
 artikel
14 Characterization of the serotonin transporter in lymphocytes and platelets of schizophrenia patients treated with atypical or typical antipsychotics compared to healthy individuals Barkan, Tal
 2006
 16 Supplement 5 p. 429-436
8 p.
 artikel
15 Chronic desipramine treatment suppresses cortical BDNF expression and ERK phosphorylation O' Sullivan, J.B.
 2006
 16 Supplement 5 p. S23-
1 p.
 artikel
16 Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats Qu, Ying
 2006
 16 Supplement 5 p. 561-571
11 p.
 artikel
17 Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate López-Gil, X.
 2006
 16 Supplement 5 p. S46-S47
2 p.
 artikel
18 Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice Kuzmin, Alexander
 2006
 16 Supplement 5 p. 129-136
8 p.
 artikel
19 C.14.01 The acute patient - efficacy without sedation Cañas, F.
 2006
 16 Supplement 5 p. S583-
1 p.
 artikel
20 C.16.03 The importance of serotonin (5-HT) and noradrenaline (NA) in anxiety Blier, P.
 2006
 16 Supplement 5 p. S586-
1 p.
 artikel
21 C.15.01 Treating depression today: clinical reality in using antidepressants Kennedy, S.
 2006
 16 Supplement 5 p. S584-
1 p.
 artikel
22 Depression and associated sleep disturbances: patient benefits with agomelatine Kupfer, David J.
 2006
 16 Supplement 5 p. S639-S643
5 p.
 artikel
23 Dopamine D2 receptor gene variants and quantitative measures of positive and negative symptom response following clozapine treatment Hwang, Rudi
 2006
 16 Supplement 5 p. 248-259
12 p.
 artikel
24 Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test Consoni, Fernando T.
 2006
 16 Supplement 5 p. 451-458
8 p.
 artikel
25 ECNP Calendar of Events 2006
 16 Supplement 5 p. I-
1 p.
 artikel
26 2007 ECNP Workshop: Announcement 2006
 16 Supplement 5 p. II-
1 p.
 artikel
27 Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice Kos, T.
 2006
 16 Supplement 5 p. 297-310
14 p.
 artikel
28 Effect of vitamin E on memory retention in rats: Possible involvement of cholinergic system Eidi, Akram
 2006
 16 Supplement 5 p. 101-106
6 p.
 artikel
29 Effects of chronic treatment with fluvoxamine and paroxetine during adolescence on serotonin-related behavior in adult male rats de Jong, Trynke R.
 2006
 16 Supplement 5 p. 39-48
10 p.
 artikel
30 Escitalopram versus paroxetine for social anxiety disorder: An analysis of efficacy for different symptom dimensions Stein, Dan J.
 2006
 16 Supplement 5 p. 33-38
6 p.
 artikel
31 E.04.02 Treatment of adult ADHD Taylor, E.
 2006
 16 Supplement 5 p. S206-
1 p.
 artikel
32 GABAA receptor modulation of 5-HT neuronal firing in the median raphe nucleus: Implications for the action of anxiolytics Judge, Sarah J.
 2006
 16 Supplement 5 p. 612-619
8 p.
 artikel
33 GABAB receptor positive modulation attenuates selected molecular markers relevant to cocaine and nicotine dependence Lhuillier, L.
 2006
 16 Supplement 5 p. S11-S12
2 p.
 artikel
34 GABAergic regulation of anxiety, memory and sensory perception Möhler, H.
 2006
 16 Supplement 5 p. S1-
1 p.
 artikel
35 Genetic polymorphisms of alcohol and aldehyde dehydrogenase, dopamine and serotonin transporters in familial and non-familial alcoholism Choi, Ihn-Geun
 2006
 16 Supplement 5 p. 123-128
6 p.
 artikel
36 Hypofunction of the dorsal hippocampal NMDA receptors impairs retrieval of memory to partially presented foreground context in a single-trial fear conditioning in rats Melik, Enver
 2006
 16 Supplement 5 p. 241-247
7 p.
 artikel
37 Imipramine treatment ameliorates corticosterone-induced alterations in the effects of 5-HT1A and 5-HT4 receptor activation in the CA1 area of rat hippocampus Zahorodna, Agnieszka
 2006
 16 Supplement 5 p. 383-390
8 p.
 artikel
38 Increased use of mental health services related to Isotretinoin treatment: A 5-year analysis Friedman, Tal
 2006
 16 Supplement 5 p. 413-416
4 p.
 artikel
39 Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist Montgomery, Stuart A.
 2006
 16 Supplement 5 p. S633-S638
6 p.
 artikel
40 MDMA (“ECSTASY”) suppresses innate IFN-gamma production and signalling, and inhibits MHC II expression on APCs Boyle, N.T.
 2006
 16 Supplement 5 p. S25-S26
2 p.
 artikel
41 Melatonin affects the immobility time of rats in the forced swim test: The role of serotonin neurotransmission Micale, Vincenzo
 2006
 16 Supplement 5 p. 538-545
8 p.
 artikel
42 On the role of serotonin 1B (5-HT1B) receptors in cocaine- or food-maintained behaviour in rats Golda, A.
 2006
 16 Supplement 5 p. S45-S46
2 p.
 artikel
43 P.8.a.053 A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder Gharabawi, G.M.
 2006
 16 Supplement 5 p. S562-
1 p.
 artikel
44 P.4.a.003 Aripiprazole augmentation of fluvoxamine in poor-insight obsessive-compulsive patients Panigada, F.
 2006
 16 Supplement 5 p. S450-
1 p.
 artikel
45 P.3.a.036 Association between polymorphisms of the 5HT2A receptor gene and positive symptom response to olanzapine treatment in patients with schizophrenia Olajossy-Hilkesberger, L.
 2006
 16 Supplement 5 p. S384-
1 p.
 artikel
46 P.3.a.022 Beneficial effect of short-term testosterone adjuvant treatment for negative symptoms of male schizophrenia Ko, Y.H.
 2006
 16 Supplement 5 p. S376-
1 p.
 artikel
47 P.2.a.035 Clinical characteristics of depressive episodes in Bipolar I and Bipolar II disorders Linotte, S.
 2006
 16 Supplement 5 p. S301-
1 p.
 artikel
48 P.8.a.021 Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with ADHD Biederman, J.
 2006
 16 Supplement 5 p. S545-S546
2 p.
 artikel
49 P.2.a.007 “Difficult depression” at private psychiatric clinics throughout France: an epidemiological survey (DEDICACE survey) Bougerol, T.
 2006
 16 Supplement 5 p. S286-S287
2 p.
 artikel
50 P.8.a.039 Driving ability in adults with attention-deficit hyperactivity disorder significantly improves when treated with methylphenidate Verster, J.C.
 2006
 16 Supplement 5 p. S554-S555
2 p.
 artikel
51 P.8.a.036 Effective pain reduction of non-pharmacological interventions for procedural pain during repetitive immunizations of children born pre-term Petrilli, G.
 2006
 16 Supplement 5 p. S553-
1 p.
 artikel
52 P.3.a.019 Efficacy and safety of ziprasidone and clozapine in treatment refractory schizophrenic patients:results of a randomized, double-blind, 18-week trial Sacchetti, E.
 2006
 16 Supplement 5 p. S374-
1 p.
 artikel
53 P.3.a.005 Exploring the socio-cultural components of prescription patterns in schizophrenia: a comparative study Xiang, Y.T.
 2006
 16 Supplement 5 p. S366-S367
2 p.
 artikel
54 P.1.a.014 Expressed gene differences on .uoxetine treatment in rat hippocampus Paik, K.C.
 2006
 16 Supplement 5 p. S215-S216
2 p.
 artikel
55 P.2.a.020 High cholesterol, triglycerides, and body-mass index in suicide attempters: a population-based study Brunner, J.
 2006
 16 Supplement 5 p. S293-S294
2 p.
 artikel
56 P.1.a.008 5-HTTLPR polymorphism of the serotonin transporter gene and history of suicide attempts in schizophrenic patients Godlewska, B.
 2006
 16 Supplement 5 p. S212-
1 p.
 artikel
57 P.2.a.010 L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression Lojko, D.
 2006
 16 Supplement 5 p. S288-
1 p.
 artikel
58 P.8.a.004 Nocturnal eating episodes after taking zolpidem: are they sleep problems or eating problems? Kim, J.M.
 2006
 16 Supplement 5 p. S536-S537
2 p.
 artikel
59 P.6.a.003 Oxcarbazepine in alcohol relapse prevention - a randomized open trial Croissant, B.
 2006
 16 Supplement 5 p. S491-
1 p.
 artikel
60 P.1.a.001 Serotonin 5-HT1B gene polymorphism (C129T) in homicidal schizophrenics Wang, S.K.
 2006
 16 Supplement 5 p. S209-
1 p.
 artikel
61 P.4.a.018 The effects of D-cycloserine on a cognitive function task under different states of anxiety in healthy volunteers Bailey, J.E.
 2006
 16 Supplement 5 p. S457-S458
2 p.
 artikel
62 P.2.b.008 Antidepressant-like activity of Wf-516, an antagonist of 5-HT1A receptors and inhibitor of 5-HT reuptake, in a chronic mild stress model of depression in rat Papp, M.
 2006
 16 Supplement 5 p. S305-S306
2 p.
 artikel
63 P.2.b.017 Biologic epistasis between SERT and BDNF: complex genetic mechanisms of depression Pezawas, L.P.
 2006
 16 Supplement 5 p. S310-S311
2 p.
 artikel
64 P.2.b.014 Does the antidepressive response to opiate treatment describe a subtype of depression? Nyhuis, P.W.
 2006
 16 Supplement 5 p. S309-
1 p.
 artikel
65 P.6.b.003 Dopamine-related gene polymorphisms and alcohol withdrawal symptoms in patients with alcohol dependence Kee, B.
 2006
 16 Supplement 5 p. S498-
1 p.
 artikel
66 P.8.b.014 Effects of 5-HT-2 receptor blocker (naftidrofuryl) on CMS functional state in elderly post-stroke patients Kuznetsova, S.M.
 2006
 16 Supplement 5 p. S570-
1 p.
 artikel
67 P.3.b.004 Evidence of a cortical disinhibition in schizophrenia: a transcranial magnetic stimulation study Ben Amor, C.
 2006
 16 Supplement 5 p. S393-S394
2 p.
 artikel
68 P.2.b.001 Expression of genes related to 5-HT neurotransmission: regulation by citalopram in a rat model of depression Flugge, G.
 2006
 16 Supplement 5 p. S302-
1 p.
 artikel
69 P.8.b.007 Gaboxadol does not generalise to other sleep-enhancing agents in drug discrimination in rats McDonald, L.M.
 2006
 16 Supplement 5 p. S567-
1 p.
 artikel
70 P.4.b.006 Inhibition of nitric oxide synthase in the dorsolateral periaqueductal grey decreases behavioural consequences of predator exposure in rats Aguiar, D.C.
 2006
 16 Supplement 5 p. S462-S463
2 p.
 artikel
71 P.3.b.001 Polymorphisms of dysbindin gene (DTNBP1) and schizophrenia in the Korean population Jun, T.Y.
 2006
 16 Supplement 5 p. S391-S392
2 p.
 artikel
72 P.1.b.012 Relationship between kynurenines and S100b in CSF of schizophrenic patients Schwarz, M.J.
 2006
 16 Supplement 5 p. S223-
1 p.
 artikel
73 P.5.b.001 The role of hippocampal phospholipase A2 in memory retrieval in rats Schaeffer, E.L.
 2006
 16 Supplement 5 p. S482-
1 p.
 artikel
74 P.4.c.001 Adjunctive quetiapine for SRI-resistant obsessive compulsive disorder: a meta-analysis of three randomised controlled treatment trials Fineberg, N.A.
 2006
 16 Supplement 5 p. S464-S465
2 p.
 artikel
75 P.1.c.030 Antidepressant treatment reduces fos-like immunoreactivity in different regions of periaqueductal gray matter Oliveira, R.M.W.
 2006
 16 Supplement 5 p. S239-S240
2 p.
 artikel
76 P.6.c.009 Benzodiazepine dependence disorder in a detoxification unit-aprospective study from 1993 to 2003 Espluga Frigola, N.
 2006
 16 Supplement 5 p. S505-
1 p.
 artikel
77 P.3.c.036 Clinical efficacy, body weight change and cardiac safety of zotepine in schizophrenic patients Lin, W.W.
 2006
 16 Supplement 5 p. S415-S416
2 p.
 artikel
78 P.3.c.041 −759 C/T polymorphism of the 5-HT2C receptor gene and antipsychotic drug-induced weight gain Ryu, S.H.
 2006
 16 Supplement 5 p. S418-S419
2 p.
 artikel
79 P.1.c.049 Descending serotonergic pathways play an inhibitory or facilitatory role in spinal pain processing by 5-HT7 or 5-HT3 receptors in acute and chronic pain Dogrul, A.
 2006
 16 Supplement 5 p. S249-S250
2 p.
 artikel
80 P.6.c.012 Differential traits in cannabis use disorder patients in a detoxification unit Mateu, G.
 2006
 16 Supplement 5 p. S507-
1 p.
 artikel
81 P.2.c.011 Effects of a phytopharmacal triple combination of St. John's wort, valerian and passion flower on sleep EEG, cognitive performance and mood: a double-blind randomised cross-over study in healthy volunteers Hemmeter, U.M.
 2006
 16 Supplement 5 p. S318-
1 p.
 artikel
82 P.1.c.039 Effects of aripiprazole on dopamine and 5-HT function in rabbit brain Kawamura, T.
 2006
 16 Supplement 5 p. S244-S245
2 p.
 artikel
83 P.1.c.017 F15599, a highly selective serotonin 5-HT1A receptor agonist: in vitro affinity and efficacy profile at native rat and recombinant human 5-HT1A receptors Newman-Tancredi, A.
 2006
 16 Supplement 5 p. S232-S233
2 p.
 artikel
84 P.1.c.018 F15599, a highly selective serotonin 5-HT1A receptor agonist: in vivo profile in neurochemical and behavioural models of serotonergic activity Assié, M.B.
 2006
 16 Supplement 5 p. S233-
1 p.
 artikel
85 P.2.c.025 Gender differences in patient's acceptance of mirtazapine orally disintegrating tablet in Lithuanian clinical practice Danileviciute, V.
 2006
 16 Supplement 5 p. S326-
1 p.
 artikel
86 P.1.c.019 5-HT2A/2C receptors modulate behaviour and c-fos expression in ovariectomized rats in forced swim test Barabanova, S.
 2006
 16 Supplement 5 p. S234-
1 p.
 artikel
87 P.1.c.002 Influence of nootropil on neuroplasticity of the brain cortex in conditions of hypokinesia Melkonyan, K.
 2006
 16 Supplement 5 p. S224-S225
2 p.
 artikel
88 P.2.c.024 Is mirtazapine in combination with perospirone efficacious in drug resistant depression? - Via 5-HT1A receptor activation Morita, M.
 2006
 16 Supplement 5 p. S325-S326
2 p.
 artikel
89 P.1.c.040 Long-lasting cognitive enhancing effects of S 18986, a positive modulator of AMPA receptors, in the object recognition task in rats Bertaina-Anglade, V.
 2006
 16 Supplement 5 p. S245-
1 p.
 artikel
90 P.2.c.028 Mirtazapine use during pregnancy - a report of 8 cases Janu, J.-.L.
 2006
 16 Supplement 5 p. S328-
1 p.
 artikel
91 P.1.c.016 New tranquilizers - prodrugs for slow and prolonged release by oral administration Kravchenko, I.A.
 2006
 16 Supplement 5 p. S232-
1 p.
 artikel
92 P.3.c.019 Patient compliance and efficacy of quetiapine treatment in schizophrenia: results of six-month follow-up study Alptekin, K.
 2006
 16 Supplement 5 p. S406-S407
2 p.
 artikel
93 P.7.c.005 Pharmacokinetics, detection, likeability and dislikeability of two formulations of long-acting oral methylphenidate Spencer, T.J.
 2006
 16 Supplement 5 p. S529-
1 p.
 artikel
94 P.3.c.053 Prevalence of aggressive episodes among ambulatory patients with schizophrenia: focus on past and recent events Bobes, J.
 2006
 16 Supplement 5 p. S425-
1 p.
 artikel
95 P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study Arango, C.
 2006
 16 Supplement 5 p. S423-S424
2 p.
 artikel
96 P.1.c.032 Regulation of NA and GABA systems on DOI (agonist 5-HT2A/2C) anxiolytic-like effect in the four-plate test and cerebral localization of target receptors Masse, F.
 2006
 16 Supplement 5 p. S240-S241
2 p.
 artikel
97 P.7.c.002 Risperidone versus haloperidol in the treatment of children with Tourette's syndrome and chronic motor or vocal tic disorder in Korea Lim, L.K.Y.
 2006
 16 Supplement 5 p. S527-
1 p.
 artikel
98 P.1.c.043 The effects of risperidone, olanzapine and haloperidol on enzyme activities in kidney tissue of rats Gulaboglu, M.
 2006
 16 Supplement 5 p. S246-S247
2 p.
 artikel
99 P.3.c.009 Valproate and psychotropic drug interactions Glen, J.
 2006
 16 Supplement 5 p. S401-
1 p.
 artikel
100 P.6.d.010 Adverse effects of maternal pre-mating opiate exposure on anxiety-related behaviour and nociception in the offspring Shamakina, I.Y.
 2006
 16 Supplement 5 p. S512-
1 p.
 artikel
101 P.1.d.008 Alterations in the functional activity of the prodynorphin gene expression in selected brain regions are associated to increased preference for ethanol and the development of dependence Oliva, J.M.
 2006
 16 Supplement 5 p. S253-S254
2 p.
 artikel
102 P.6.d.024 C385A FAAH SNP is related to substance use disorder but not to schizophrenia in a Spanish sample Martínez-Gras, I.
 2006
 16 Supplement 5 p. S519-S520
2 p.
 artikel
103 P.6.d.023 Differential potencies of Ecstasy derivatives in [3H] 5-HT uptake and evoked release from rat hippocampal slices Pasquier, F.D.
 2006
 16 Supplement 5 p. S519-
1 p.
 artikel
104 P.1.d.018 Effect of dopamine depletion and 5-HT1B receptors blockade on the behavioural effect of various antidepressant in the mice FST Chenu, F.
 2006
 16 Supplement 5 p. S259-
1 p.
 artikel
105 P.1.d.004 Effects of a selective and brain penetrating 5-HT6 receptor antagonist in animal models of depression and anxiety Wesolowska, A.
 2006
 16 Supplement 5 p. S251-S252
2 p.
 artikel
106 P.3.d.005 Effects of novel antipsychotics with preferential activity at D2-like and 5-HT1A receptors, in comparison with typical and atypical reference antipsychotics, in rodent models of cognition and memory deficit Bardin, L.
 2006
 16 Supplement 5 p. S431-S432
2 p.
 artikel
107 P.3.d.008 Effects of novel antipsychotics with preferential activity at D2-like and 5-HT1A receptors, in comparison with typical and atypical reference antipsychotics, in rodent models of cognitive flexibility and sensory-motor gating Auclair, A.L.
 2006
 16 Supplement 5 p. S433-
1 p.
 artikel
108 P.6.d.007 Evaluation of the role of 5-HT1A receptors in dorsal and median raphe nuclei on the morphine withdrawal syndrome in rat Charkhpour, M.
 2006
 16 Supplement 5 p. S510-S511
2 p.
 artikel
109 P.3.d.009 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: II. Profile in models predictive of efficacy against positive, negative symptoms and cognitive deficits of schizophrenia Depoortere, R.
 2006
 16 Supplement 5 p. S434-
1 p.
 artikel
110 P.3.d.004 F15063, a novel antipsychotic with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: I. Receptor affinity and efficacy in vitro and activity in neurochemical and neuroendocrine tests in rodents Newman-Tancredi, A.
 2006
 16 Supplement 5 p. S431-
1 p.
 artikel
111 P.3.d.007 F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III. Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents Assié, M.B.
 2006
 16 Supplement 5 p. S432-S433
2 p.
 artikel
112 P.2.d.024 5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats: clinical implications Sukoff Rizzo, S.J.
 2006
 16 Supplement 5 p. S345-S346
2 p.
 artikel
113 P.2.d.005 In vivo electrophysiological assessment of the putative antidepressant Wf-516 in raphe dorsalis, locus coeruleus and hippocampus in the rat brain El Mansari, M.
 2006
 16 Supplement 5 p. S335-
1 p.
 artikel
114 P.3.d.021 Physostigmine reverses MK-801-induced but not amphetamine-induced effects on latent inhibition: focus on cholinergic treatments in schizophrenia Barak, S.
 2006
 16 Supplement 5 p. S440-S441
2 p.
 artikel
115 P.2.d.022 The modified Tail Suspension Test (mTST): a new paradigm to categorize antidepressants. Effects of classical and atypical opiates Berrocoso, E.
 2006
 16 Supplement 5 p. S344-S345
2 p.
 artikel
116 P.1.e.007 Atypical and typical antipsychotics differentially reverse abnormal brain functional MRI signals in a neurodevelopmental model of schizophrenia Moreau, J.L.
 2006
 16 Supplement 5 p. S262-
1 p.
 artikel
117 P.1.e.004 Cingulate glutamatergic signals distinguish adult patients with ADHD from healthy controls - a magnetic resonance spectroscopy study Perlov, E.
 2006
 16 Supplement 5 p. S261-
1 p.
 artikel
118 P.3.e.001 Impact of the obesity on the use of antipsychotic drugs in a Spanish adult population setting Sicras Mainar, A.
 2006
 16 Supplement 5 p. S442-
1 p.
 artikel
119 P.1.e.021 Neural correlates of emotional self in bipolar disorder: a BOLD functional MRI 3 T study Radaelli, D.
 2006
 16 Supplement 5 p. S270-S271
2 p.
 artikel
120 P.4.e.004 Trait stability and agoraphobia in a one year follow up panic disorder sample Hoyuela, F.
 2006
 16 Supplement 5 p. S472-S473
2 p.
 artikel
121 P.2.e.008 Validity and reliability of the Spanish version of the Bech-Rafaelsen's mania (MAS) and melancholia (MES) scales for bipolar disorders Bobes, J.
 2006
 16 Supplement 5 p. S350-
1 p.
 artikel
122 P.1.f.011 Global impairment in the controlled access to the episodic autobiographical memory in depression: state or trait marker? Bergouignan, L.
 2006
 16 Supplement 5 p. S279-
1 p.
 artikel
123 P.2.f.002 Plasma brain-derived neurotrophic factor and neurocognitive correlates in euthymic bipolar patients: preliminary results Dias, V.V.
 2006
 16 Supplement 5 p. S357-
1 p.
 artikel
124 P.5.f.001 SSR180711, an α7 nicotinic receptor partial agonist, reverses memory deficits induced by β25-35 amyloid peptide icv administration in mice Urani, A.
 2006
 16 Supplement 5 p. S489-
1 p.
 artikel
125 P.3.f.002 The 5-HT6 receptor antagonists, SB271,046 and SB258,585, enhance social memory and cholinergic transmission in rats: a comparison with 5-HT1A receptor partial agonists Loiseau, F.
 2006
 16 Supplement 5 p. S447-S448
2 p.
 artikel
126 P.2.g.003 The role of SSRIs in treatment of patients with irritable bowel syndrome Tosic Golubovic, S.T.G.
 2006
 16 Supplement 5 p. S359-
1 p.
 artikel
127 Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? Hamon, M.
 2006
 16 Supplement 5 p. S625-S632
8 p.
 artikel
128 Possible genetic implications of the endocannabinoid system in anxiety disorders versus depressive disorders Erhardt, A.
 2006
 16 Supplement 5 p. S88-
1 p.
 artikel
129 Prenatal stress in rats attenuates hippocampal long-term potentiation and induces deficits in synaptic plasticity Salomon, S.
 2006
 16 Supplement 5 p. S52-
1 p.
 artikel
130 Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment Cohen, D.
 2006
 16 Supplement 5 p. 187-194
8 p.
 artikel
131 Protective effect of vineatrol against kainic acid induced seizures, oxidative stress and on the expression of heat shock proteins in rats Gupta, Yogendra Kumar
 2006
 16 Supplement 5 p. 85-91
7 p.
 artikel
132 S.19.03 Birth injury and the psychosis pathway: insights from animal models of obstetric complications Boksa, P.
 2006
 16 Supplement 5 p. S192-
1 p.
 artikel
133 S.04.08 Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate López-Gil, X.
 2006
 16 Supplement 5 p. S172-
1 p.
 artikel
134 Serotonin transporter characteristics in lymphocytes and platelets of male aggressive schizophrenia patients compared to non-aggressive schizophrenia patients Barkan, Tal
 2006
 16 Supplement 5 p. 572-579
8 p.
 artikel
135 Serotonin uptake to lymphocytes of patients with social phobia compared to normal individuals Barkan, Tal
 2006
 16 Supplement 5 p. 19-23
5 p.
 artikel
136 Sex-dependent effects of fluoxetine and triiodothyronine in the forced swim test in rats Lifschytz, Tzuri
 2006
 16 Supplement 5 p. 115-121
7 p.
 artikel
137 S.04.06 Fluorescence in vitro studies of human dopamine D1 and D2 receptor proteins interaction Faron-Gorecka, A.
 2006
 16 Supplement 5 p. S171-S172
2 p.
 artikel
138 S.15.05 Impulsivity and compulsivity: translational .ndings on the role of dopamine Westenberg, H.G.M.
 2006
 16 Supplement 5 p. S187-
1 p.
 artikel
139 Single or low dose of ecstasy, is it safe? A prospective study on neurotoxicity of ecstasy in new ecstasy users de Win, M.M.L.
 2006
 16 Supplement 5 p. S79-S80
2 p.
 artikel
140 S.25.02 Molecular genetics of smoking and co-morbid psychiatric disorders Munafo, M.
 2006
 16 Supplement 5 p. S200-
1 p.
 artikel
141 S.10.04 Neurocognitive deficits in pathological gambling and related disorders Goudriaan, A.E.
 2006
 16 Supplement 5 p. S182-
1 p.
 artikel
142 S.16.04 Peripheral gene expression in PTSD Shalev, A.Y.
 2006
 16 Supplement 5 p. S188-
1 p.
 artikel
143 S.01.04 Psycho-education in management of schizophrenia Höschl, C.
 2006
 16 Supplement 5 p. S165-S166
2 p.
 artikel
144 S.25.05 Smoking cessation treatment in patients with schizophrenia: outcomes, relapse vulnerability factors, and targeted interventions George, T.P.
 2006
 16 Supplement 5 p. S201-
1 p.
 artikel
145 S.21.05 The beta-3-adrenergic receptor in anxiety disorders and their treatment Stemmelin, J.
 2006
 16 Supplement 5 p. S195-S196
2 p.
 artikel
146 S.07.07 The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results Howes, O.D.
 2006
 16 Supplement 5 p. S177-
1 p.
 artikel
147 S.07.04 Vagus nerve stimulation increases neurotrophins gene expression and alters cell proliferation in the rat hippocampus Follesa, P.
 2006
 16 Supplement 5 p. S176-
1 p.
 artikel
148 The effect of tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) and newer antidepressant drugs on the activity and level of rat CYP3A Haduch, A.
 2006
 16 Supplement 5 p. 178-186
9 p.
 artikel
149 The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress Nishitsuji, Kyoko
 2006
 16 Supplement 5 p. 376-382
7 p.
 artikel
                             149 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland